The UK Breast Cancer Research Symposium 2016 is an interdisciplinary two day conference delivered by experts in the breast cancer research field. This brings together researchers, clinicians, patient groups and organisations working in the field of breast cancer providing a number of commercial opportunities to interact with delegates.
Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal publishes preclinical, translational and clinical studies with a biological basis, including Phase I and Phase II trials.
Genomic Health® is a leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of cancer. With its Oncotype IQ™ Genomic Intelligence Platform, the company is applying its state-of-the-art scientific and commercial expertise and infrastructure to translate significant amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient’s journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California with UK headquarters in London.
Camurus is a Swedish research-focused pharmaceutical company dedicated to the creation of high value therapeutics addressing significant unmet medical needs. Exploiting the varied benefits of the company’s proprietary and award-winning lipid-based FluidCrystal® drug delivery technology, Camurus has developed episil® oral liquid, an innovative product for the relief of intra-oral pain associated with Oral Mucositis. In contact with the oral mucosa, episil® transforms into a strongly protective bioadhesive film, providing rapid and sustained pain relief without systemic side effects. Supplied in a ready-to-use device, episil® helps patients maintain their quality of life while undergoing cancer therapy.
The Breast Cancer Now Tissue Bank provides high-quality tissues, bloods and cells to the cancer research community. We have generic ethical approval from NRES that covers most experiments. For each sample we collect data including lifestyle data, pathological data, treatment and follow-up data. More than half of our samples have follow-up data a third of our samples have treatment information. Material is free to our funded researchers with competitive rates for other applicants. You can search and apply for material at breastcancertissuebank.org
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. Promega Corporation’s 3,500 products enable scientists worldwide to advance their knowledge in life science research, particularly in genomics, proteomics, and cellular analysis.
Our products and services support scientists asking fundamental questions about biological processes apply scientific knowledge to understand the mechanisms of disease, discover new therapeutics, and use genetics and DNA testing for human identification.
PerkinElmer’s Phenoptics™ Research Solution for cancer immunology and immunotherapy is a unique workflow, which includes multiplexed Opal™ staining reagents and methodologies, instrumentation (Vectra® Automated high-throughput Quantitative Imaging System) and advanced image analysis software (inForm® and Indica HALO®) that can be trained to phenotype cells and measure checkpoint, activation and functional markers between cells and within the tumor microenvironment. The Vectra with unique channel-separation technology enables the quantification of multiple biomarkers, revealing spatial context, all within a digital workflow.
Cambridge Bioscience is a leading provider of life science products with a passion for bringing new and exciting technologies to researchers. We offer an innovative and diverse range of high quality products, services and instruments supporting cancer research. Our portfolio includes JuLI™ Stage, a real-time, fully-automated, fluorescence cell history recorder for the imaging and recording of cells within an incubator and Avatar™, a ground-breaking cell culture incubator featuring accurate pressure, oxygen and CO2 control. We aim to only offer our customers exceptional quality products accompanied by friendly technical and customer support.
At Novartis Oncology, we are passionate about the discovery and development of innovative medicines. We seek to provide a broad range of new therapies as well as practical solutions to advance the care of patients. Novartis Oncology has an extensive portfolio of 22 oncology, haematology and rare disease medicines treating more than 25 conditions from breast and lung cancer to chronic myeloid leukaemia and acromegaly. Our broad pipeline includes 27 new molecular entities in development, targeting key molecular pathways in cancer biology.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Springer Nature is one of the world’s leading global research, educational and professional publishers, home to an array of respected and trusted brands providing quality content through a range of innovative products and services.
Springer Nature is the world’s largest academic book publisher, publisher of the world’s most influential journals and a pioneer in the field of open research. The company numbers almost 13,000 staff in over 50 countries and has a turnover of approximately EUR 1.5 billion. Springer Nature was formed in 2015 through the merger of Nature Publishing Group, Palgrave Macmillan, Macmillan Education and Springer Science+Business Media.
SEARCHBreast (Sharing Experimental Animal Resources Coordinating Holdings – breast) is an initiative focused on connecting researchers to share their resources and expertise to help drive discoveries and treatments in the breast cancer field.
At the crux of this is a virtual on-line portal whereby SEARCHBreast members have deposited excess material generated from in vivo experiments available to use on a collaborative basis. Thousands of tissue samples from syngeneic, xenograft and PDX models are ready to share in various formats. Any academic researcher can become a SEARCHBreast member through following a simple registration process on the homepage.